权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

OPTIMIZATION OF HYPERTHERMIA--CLINIC, BIOLOGY, & PHYSICS

热疗的优化——临床、生物学、

基本信息

批准号：
2712558
负责人：
STUART Keith CALDERWOOD
金额：
$ 170.57万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
1992
资助国家：
美国
起止时间：
1992-09-30 至 2001-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/2712558
关键词：
clinical research human subject hyperthermia therapy neoplasm /cancer thermotherapy prostate neoplasms

项目摘要

This program project will use a disease-site oriented approach to address the hypothesis: hyperthermia delivered as an adjuvant to radiation therapy will improve the clinical outcome of patients with prostate cancer resulting in organ preservation, a reduced probability of recurrence, improved quality of life and superior survival. Three Projects and three Cores will bring together technical, biological and clinical expertise to focus on prostate cancer hyperthermia. The proper understanding of the clinical results, whether or not they are positive, requires relating athe technical parameters of the hyperthermia treatment with basic hyperthermia biology using the appropriate tumor systems. (Bernstein 0018). Clinical Project will deliver hyperthermia to patients with prostate cancer using the ultrasound probe developed by our collaborator, De. Hynynen. Temperature and perfusion will be measured using the profilometer probes developed in this grant. A second clinical goal is to complete testing of the Focused Segmented Ultrasound machine developed in the previous grant period. A third clinical research effort will be the continued clinical evaluation of hyperthermia modifiers (initially the hypoxia modifiers) designed to enhance the efficacy of temperatures obtainable ina the clinic. (Calderwood 0019). Biology Project is focused on prostate cancers using cells, tumor models and clinical biopsies to further the understanding of clinical results. In addition to the hyperthermia modifiers already developed for Project 1 the new classes of agents to be studied are the non-steroidal antiinflammatory agents and kinase inhibitors. (Newman 0017). Technology Project will develop the models and techniques required to allow hyperthermia to be used conveniently and routinely in the clinic, focusing on the use of perfusion data to adjust power deposition so that tahe targeted temperature can be maintained. (Svensson 9001). Technical, supports the clinical trials and the modeling efforts; (Teicher 9002). Animals, includes both small animals for the biologic experiments and large animals for testing the models/ and Administration, provides statistical support and provides external advice. In summary, this is a disease-site oriented program which has the long-term aim of answering the question of whether or not hyperthermia is an effective adjunctive therapy to radiation therapy for patients with cancer of the prostate.

该计划项目将使用面向疾病现场的方法来解决假设：高温可作为放射治疗的辅助手段将改善前列腺癌患者的临床结局导致器官保存，减少复发的可能性，生活质量的提高和卓越的生存。三个项目和三个 CORE将汇集技术、生物和临床专业知识重点关注前列腺癌热疗。对临床结果的正确理解，无论它们是否阳性，需要有关热疗的技术参数使用适当的肿瘤进行基础热疗生物学治疗系统。 (伯恩斯坦0018)。临床项目将为患者带来高热使用我们开发的超声探头治疗前列腺癌合作者，de.海宁。将测量体温和血流灌注量使用在这项资助中开发的轮廓仪探头。第二个临床目标是完成聚焦分段超声机的测试在前一个授权期内开发的。第三项临床研究工作将继续对热疗调节剂进行临床评估 (最初是低氧调节剂)旨在增强诊所内可获得的温度。 (考德伍德0019)。生物项目的重点是前列腺癌细胞、肿瘤模型和临床活检以加深对临床结果。除了体温过高的调节剂之外为项目1开发的要研究的新代理类别是非类固醇抗炎药和激酶抑制剂。 (纽曼0017)。技术项目将开发模型和技术需要允许热疗方便和常规地在临床上，重点是使用血流灌注数据来调整能量沉积塔河的目标温度可以维持。 (Svensson 9001)。技术，支持临床试验和建模努力；(Teicher 9002)。动物，包括两种小动物用于测试模型的生物实验和大型动物/和管理，提供统计支持，并提供外部咨询。总而言之，这是一个以疾病现场为导向的计划，具有长期的目的是回答高热是否是一种癌症患者放射治疗的有效辅助治疗前列腺的组织。